Shares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure.
The embryo viability product is being developed by Novocellus, which is 82% owned by Angle.
The firm had already said the trial of EmbryoSure was delayed, but today added that the timeframe for completing the trials was "at present uncertain".
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Agnle would meet with Origio, the firm responisble for the trials, at the end of this month to review options for progressing the trials, it said.
"We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible," said chief executive Andrew Newland.
Angle's share price fell 6% after the announcement.
-
Are you one of 15 million people at risk of retirement poverty?Two-fifths of people in the UK aren’t on track for a minimum lifestyle in retirement, new data shows. Are there steps you can take to boost your pension?
-
150 banking hubs now open across UK – is there one near you?As the 150th banking hub opens its doors, a Post Office deal that offers basic banking services has also been extended until 2030. We explain what this means for you
